Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

LOGIN TO START A DISCUSSION
Filter by Practice
Practice
Virginia D. Anderson
May 05, 2017 12:55 PM
The National Coalition for Cancer Survivorship (NCCS) is now accepting submissions for its Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care. The award will recognize exceptional providers whose focus on quality care has touched all aspects of cancer care, including respecting...
Practice
ASCO Admin
May 04, 2017 4:08 PM
This question was posed by an attendee at the 2017 Genitourinary Cancers Symposium. What do you think?
Should men with DNA break repair mutations (BRCA1, BRCA2, ATM, etc) found on a genetic test, but who otherwise have low-risk disease, be considered for surveillance? What is the data?
Practice
Anne Katz, PhD, RN, FAAN
Aug 26, 2016 1:08 PM
Scalp cooling has been shown to be somewhat effective in preventing chemotherapy-related alopecia. What do you recommend to your patients, especially women with breast cancer? Does your infusion center or chemotherapy unit allow or promote this? How many patients use this and what are the patient...
Practice
Mark R. Hutchins, MD
Apr 26, 2016 10:50 PM
 
Has there ever been a PRCT of AC/T vs "other" in a pure TNBC stratified group (in the NeoAdj setting or the Adj setting?) showing that AC/T vs "other" showed a superior survival? When we say that AC/T shows a survival advantage, advantage over what?
The origninal AC vs CMF showed little if any...
Practice
Arsh Singh, MD
Jan 18, 2016 1:00 PM
In a 33 y/o caucasian woman with T2N0 Her 2 Positive invasive ductal carcinoma (both by IHC and FISH), ER 50% and PR negative, is it okay to use AC followed by T along with herceptin and pertuzumab  in the neoadjuvant setting?

Pages

Tweets from ASCO

Tweets from Oncology Community